NCT07322965Recruiting
Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma
Evaluation of the Effect of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma
Source: ClinicalTrials.gov · Last updated 14 Jan 2026
Brief summary (registry, in English)
This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial. This is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence. The trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function. The results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- First submitted
- 25 Mar 2025
- Start date
- Apr 2025
- Primary completion date
- Apr 2027
- Lead sponsor
- Institut Catala de Retina
- Diseases
- Glaucoma
- NCT number
- NCT07322965
What you commit to
- Study type: Interventional
- Planned participants: 108
- From Apr 2025 to the primary completion date, Apr 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of any vitamin or nutraceutical supplement in the month prior to screening.
- Any condition that could alter visual field testing, including:
- Neurological diseases. Retinal diseases. Advanced cataracts. Treatment with Lyrica (Pregabalin) due to its effect on visual fields.
- Ocular surgery or laser treatment in the 3 months prior to enrollment or planned during the study.
Other illness
- Hypersensitivity to acetylsalicylic acid (aspirin) (cross-reactivity risk with citicoline).
Other
- Mean Deviation (MD) of the visual field worse than -20 dB or better than -3 dB.
Who the study is looking for
- Patients with chronic glaucoma (primary or secondary, open-angle or closed-angle) diagnosed in at least one eye, meeting the following criteria:
- Structural damage: Thinning of the neuroretinal rim, peripapillary hemorrhage, or reduction in the nerve fiber layer, confirmed by OCT or color fundus photography.
- Functional damage: At least 3 contiguous abnormal points outside the 95% confidence limit in the pattern deviation map of the visual field.
- At least 4 reliable visual field (VF) tests before study enrollment.
- Age between 50 and 75 years.
- If both eyes meet the inclusion criteria, the eye with the worst Mean Deviation (MD) will be selected as the study eye.
Age in the registry: 50 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Català de Retina Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| Hospital del Mar | Centre Esperança Coordinator of this site? Confirm its status | Barcelona | Spain | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.